Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.
Back
Early Identification of TP53 Mutations Via IHC in AML and MDS
Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations MDS and AML.
Early Identification of TP53 Mutations Via IHC in AML and MDS
Episodes
All
All
Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the next steps for validating IHC as a biomarker for TP53 mutations in MDS and AML.
Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.
Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Dr Lee on the Optimal Duration of Adjuvant Osimertinib in EGFR+ NSCLC
5